Marijuana is one of the least studied drugs due to it being federally illegal, however, more and more studies are coming out discussing the benefits of marijuana. The UK has made a large leap in a positive direction towards the marijuana movement.
Cannabinoid biotechnology company, MediPen, is launching its own dedicated marijuana research facility this summer. This new 1,800 square-foot research facility will help boost innovation and inquiry in the marijuana research field.
The goal of the company is to work with and import controlled compounds, including THC to further research for marijuana. As a respected company and an advocate for marijuana, MediPen joined a contract with the country’s National Health Service to improve the quality and safety of cannabinoid goods.
MediPen was the first biotechnology company to develop a vapor product and has celebrated numerous successes from their products. These products include their non-psychoactive CBD vaporizers, which are currently in the process of securing a license from the British Home Office.
According to HighTimes “Their devices were tested by an NHS [National Health Service] unit, an unprecedented and important step that helped focus and increase attention on the medical benefits of cannabis.”
With their new research facility, MediPen intends to study the use of vaporizers to treat cancer patients. The aim of their research would be towards the goal of minimizing the negative impact of chemotherapy-based treatments, such as nausea and vomiting. They would also like to include in the research how using vaporizers could help to attempt to suppress metastasis through inhibiting the proliferation of cancer cells.
“As it stands, there is a significant amount of scientific data available detailing the powerful effects of cannabinoids within cell culture systems and in vivo,” a MediPen representative told the Independent. “However, we plan to be amongst the first in the world to begin clinical trials on humans.”
MediPen intends to allow the use of their facilities to founders of other cannabis companies pursuing innovation and research in the field.